Gadolinium-hematoporphyrin: New potential MRI contrast agent for detection of breast cancer cell line (MCF-7)

Journal of Research in Medical Sciences

Volumn 10, Issue 5, 2005, Pages 309-313

  Shahbazi Gahrouei, Daryaoush ^a,b   Tavakoli, M B ^a   Nazari, V ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer cell (MCF 7); Contrast agent; Hematporphyrin; MRI; Porphyrin

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; HEMATOPORPHYRIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CELL MEMBRANE; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAXATION TIME; SIGNAL DETECTION; STRUCTURE ANALYSIS; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 29244476508     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Nelson J, Schmiedl U. Porphyrins as contrast media. Magn Reson Med 1991; 22: 366-71.
2. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of Gadolinium(III) texaphyrin complex: a new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994; 29(3): 330-8.
3. Ni Y, Petre C, Miao Y, Yu J, et al. Magnetic resonance imaging: histomorphologic correlation studies on paramagnetic metalloporphyrins in rat model of necrosis. Invest Radiol 1997; 32(12): 770-9.
4. Furmanski P, Longley C. Metalloporphyrin contrast enhancement of magnetic imaging of human tumor xenografts in nude mice. Cancer Research 1988; 48: 4604-10.
5. Oagan MD, Revel D, Brasch RC. Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging: a study of human carcinoma, lymphoma, and fibrosarcoma in mice. Invest Radiol 1987; 22: 822-8.
6. Shahbazi-Gahrouei D, Williams M, Rizvi SM, Allen BJ. In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: potential MR imaging contrast agents for melanoma. J Magn Reson Imag 2001; 14(2): 169-74.
7. Shahbazi-Gahrouei D, Williams M, Allen. BJ Synthesis and application of Gd-porphyrins as MR imaging agent for cancer detection. Iranian Biomedical Journal 2001; 5(2&3): 87-95.
8. Shahbazi-Gahrouei D, Williams M, Allen BJ. In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength. Australasian Radiology 2001; 45(3): 298-304.
9. Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ. In-vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australas Phys Eng Sci Med 2002; 25(1): 31-8.
10. Haley TJ. Pharmacology and toxicology of the rare earth elements. J Pharm Sci 1965; 54: 663-70.
11. Lyon RC, Faustino PJ, Cohen JS, Katz A. Tissue distribution and stability of metalloporphyrin MRI contrast agents. Magn Reson Imaging 1987; 4: 24-33.
12. Ferrand Y, Bourre L, Simonneaux G, et al. Hydro porphyrins as tumor photosensitizers: synthesis and photophysical studies of 2,3-dihydro-5′15-di(3,5-dihydroxyphenyl) porphyrin. Bioorg Med Chem Lett 2003; 13: 833-5.
13. Bourre L, Simonneaux G, Ferrand Y, et al. Synthesis, in vitro and in vivo evaluation of a diphenylchlorin sensitizer for photodynamic therapy. J Photochem Photobiol B: Biology 2003; 69: 179-92.